Study on YL201 with Other Cancer Treatments for Advanced Solid Tumors
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
ClinicalTrials ID:NCT07407933
This clinical trial is testing a new drug, YL201, in combination with atezolizumab to see if it is safe and effective for patients with advanced solid tumors, specifically those with extensive stage small cell lung cancer (ES-SCLC).
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study is exploring a new treatment involving the drug YL201 combined with atezolizumab for patients with advanced solid tumors, focusing on those with extensive stage small cell lung cancer (ES-SCLC). The study has two parts. In the first part, researchers will test different doses of YL201 to find a safe and tolerable level when used with atezolizumab. In the second part, they will further refine the dose and expand the study to more participants to see how well the treatment works. Participants will continue treatment until their cancer progresses, they experience unacceptable side effects, or they choose to stop.
Eligibility Criteria
Inclusion Criteria
- Must be 18 years or older.
- Have a confirmed diagnosis of extensive stage small cell lung cancer (ES-SCLC).
- Be in good overall health with a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
- Have adequate blood cell counts and organ function.
Exclusion Criteria
- Have not received any prior systemic treatment for ES-SCLC.
- Have not been treated with drugs targeting B7H3 or topoisomerase I inhibitors.
- Do not have active brain metastases or spinal cord compression.
- Do not have a history of lung diseases like interstitial lung disease or pneumonitis.
- Do not have significant heart disease, such as severe heart failure.
Other specific criteria may apply as defined by the study protocol.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Site 1001 | 20057 | Washington D.C. | District of Columbia |
| Site 1005 | 77030 | Houston | Texas |
| Site 1002 | 22031 | Fairfax | Virginia |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.